Indeterminate genotypes of hepatitis C virus by the Abbott RealTi<i>m</i>e HCV Genotype II assay in Morocco. About eight cases resolved by a sequencing method

Mesbahi, Zineb; Kabbaj, Hakima; Malki, Houcine; Bouihat, Najat; Qrafli, Mounia; Belefquih, Bouchra; Marcil, Sarrah; Challine, Dominique; Pawlotsky, Jean‐Michel; Bouvier, M; Seffar, Myriam

doi:10.1002/jmv.25191

Cited by 4 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, another study reported this finding, and this was explained by cross-reactivity or mixed infections. Sequencing the samples with undetermined genotypes might be a significant key to resolving the ambiguity regarding the undefined genotypes and identifying more subtypes [23]. Moreover, the cause of not identifying the specific genotypes could be due to other factors, including small sample quantity or more genotypes and subtypes that have not yet been revealed.…”

Section: Discussionmentioning

confidence: 99%

Hepatitis C Virus Genotyping in Saudi Population

Hazazi¹,

Almubarak²,

Albloui³

et al. 2019

UCMS

View full text Add to dashboard Cite

Background: Hepatitis C is one of the common types of viral hepatitis that threatens human life worldwide. Hepatitis C virus (HCV) is a single-strand RNA virus that has the ability to be transmitted by contaminated blood products and intravenous drug use. HCV is characterized by its ability to have a high genetic diversity, which eventually results in different HCV genotypes and numerous subtypes; however, this genetic variety is a core reason for the lack of a successful vaccine for these types of viruses. Methods: HCV nucleic acid was isolated from 597 patients diagnosed with chronic hepatitis C in Security Forces Hospital (SFHR) in Riyadh. HCV nucleic acid was extracted to make the target accessible for amplification and genotype detection. The process of nucleic acid extraction and amplification was accomplished with the Abbott Molecular Systems m2000sp and m2000rt using the Abbott RealTime HCV Genotype II. Results: The findings in this study illustrated a major prevalence of genotype 4 (60% of cases). The study also showed a large number of patients (27%) identified as HCV genotype 1. Furthermore, the HCV genotype 1 testing detected subtypes 1a and 1b in a number of patients. It was also demonstrated that a limited number of hepatitis C patients had mixed genotypes and undermined genotypes. Conclusion: The study has confirmed that HCV genotype 4 has a high prevalence when compared to the rest of the identified genotypes. Furthermore, the majority of identified genotypes and subtypes were found to be linked with age more than 50 years, which might indicate an association of HCV genotype detection with age.

show abstract

Section: Discussionmentioning

confidence: 99%

Hepatitis C Virus Genotyping in Saudi Population

Hazazi¹,

Almubarak²,

Albloui³

et al. 2019

UCMS

View full text Add to dashboard Cite

show abstract

“…We used ART HCV assays (RealTime HCV and HCV Genotype II, Abbott Molecular, Abbott Park, IL, USA) to quantify HCV viral RNA load and genotyping. The assay detects genotypes 1, 2, 3, 4, 5, and 6, and subtypes 1a and 1b with genotype-specific fluorescent-labeled oligonucleotide probes [ 20 , 22 , 23 ]. An “indeterminate” result means a detectable HCV viral load without the ability to produce a genotype result.…”

Section: Methodsmentioning

confidence: 99%

Pan-Genotypic Direct-Acting Antiviral Agents for Undetermined or Mixed-Genotype Hepatitis C Infection: A Real-World Multi-Center Effectiveness Analysis

Yen

Chen

Lai

et al. 2022

JCM

View full text Add to dashboard Cite

Although the pan-genotypic direct-acting antiviral regimen was approved for treating chronic hepatitis C infection regardless of the hepatitis C virus (HCV) genotype, real-world data on its effectiveness against mixed-genotype or genotype-undetermined HCV infection are scarce. We evaluated the real-world safety and efficacy of two pan-genotypic regimens (Glecaprevir/Pibrentasvir and Sofosbuvir/Velpatasvir) for HCV-infected patients with mixed or undetermined HCV genotypes from the five hospitals in the Changhua Christian Care System that commenced treatment between August 2018 and December 2020. This retrospective study evaluated the efficacy and safety of pan-genotypic direct-acting antiviral (DAA) treatment in adults with HCV infection. The primary endpoint was the sustained virological response (SVR) observed 12 weeks after completing the treatment. Altogether, 2446 HCV-infected patients received the pan-genotypic DAA regimen, 37 (1.5%) patients had mixed-genotype HCV infections and 110 (4.5%) patients had undetermined HCV genotypes. The mean age was 63 years and 55.8% of our participants were males. Nine (6.1%) patients had end-stage renal disease and three (2%) had co-existing hepatomas. We lost one patient to follow-up during treatment and one more patient after treatment. A total of four patients died. However, none of these losses were due to treatment-related side effects. The rates of SVR12 for mixed-genotype and genotype-undetermined infections were 97.1% and 96.2%, respectively, by per-protocol analyses, and 91.9% and 92.7% respectively, by intention-to-treat population analyses. Laboratory adverse events with grades ≥3 included anemia (2.5%), thrombocytopenia (2.5%), and jaundice (0.7%). Pan-genotypic DAAs are effective and well-tolerated for mixed-genotype or genotype-undetermined HCV infection real-world settings.

show abstract